Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04255173
Other study ID # IMU OP
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date January 1, 2018
Est. completion date December 1, 2019

Study information

Verified date February 2020
Source Istanbul Medeniyet University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The patients who consulted to the geriatric outpatient clinic between 2018 and 2019 were included in the study. The inclusion criterions were being at or over the age of 65 and diagnosed with osteoporosis according to WHO criteria. Exclusion criteria include vertebral fracture due to known accidental traumas, history of drug therapy in the past year (biphosphonate, estrogen replacement therapy, glucocorticoids ), history of co-morbidities as malignancy, radiotherapy or chemotherapy, renal failure, hyperthyroidism, primer hyperparathyroidism, rheumatic disease or adrenal diseases.

Initially, a demographic form including age, sex, comorbidities, weight, height was filled by the participants. Body mass index (BMI, ratio of height and weight, expressed as kg/m2) calculated. Patients waist and hip circumference was measured (cm).

Fat percentage and skeletal muscle mass (SMM) was calculated by using bioimpedance analysis (BIA) (Tanita TBF 300; Tanita Corp., Tokyo, Japan). Skeletal muscle index (SMI) was calculated from BIA-based skeletal muscle mass with a formula as SMM/height [m2] [8]. ABSI is measured as waist circumference (m) / (BMI(kg)2/3x Height(m)5/6) [4].

Osteoporosis was evaluated by using dual energy x-ray absorptiometry (DXA). According to the T-scores calculated from femur neck (FN) and lumbar spine (LS), subjects divided into 3 groups as following: a) normal: T-score is greater than -1 SD, b) osteopenia: T-score is between -1 and -2.5 SD, c) osteoporosis: T-score is lower than -2.5 SD.

Physical activity levels of patients were evaluated with The Rapid Assessment of Physical Activity (RAPA) aerobic assessment [9]. Patients divided into 5 groups as following: 1 = sedentary, 2 = underactive, 3 = regular underactive (light activities), 4 = regular underactive, and 5 = regular active).

The study protocol was approved by the ethics committee (2018/0478) and all participants gave written informed consent.


Recruitment information / eligibility

Status Completed
Enrollment 571
Est. completion date December 1, 2019
Est. primary completion date November 1, 2019
Accepts healthy volunteers No
Gender All
Age group 65 Years and older
Eligibility Inclusion Criteria:

- being at or over the age of 65

- diagnosed with osteoporosis according to WHO criteria

Exclusion Criteria:

- vertebral fracture due to known accidental traumas

- history of drug therapy in the past year (biphosphonate, estrogen replacement therapy, glucocorticoids )

- history of co-morbidities as malignancy, radiotherapy or chemotherapy, renal failure, hyperthyroidism, primer hyperparathyroidism, rheumatic disease or adrenal diseases

Study Design


Intervention

Diagnostic Test:
Body mass index
Body mass index is calculated as a ratio of height and weight, expressed as kg/m2
waist circumference
waist circumference is measured as cm
hip circumference
hip circumference is measured as cm
height
height is measured as cm
Fat percentage
Fat percentage and skeletal muscle mass (SMM) was calculated by using bioimpedance analysis (BIA) (Tanita TBF 300; Tanita Corp., Tokyo, Japan).
Skeletal muscle index
Skeletal muscle index (SMI) was calculated from BIA-based skeletal muscle mass with a formula as SMM/height [m2].
A body shape index (ABSI)
ABSI is measured as waist circumference (m) / (BMI(kg)2/3x Height(m)5/6)
Dual energy x ray absorptiometry (DXA)
Osteoporosis is diagnosed with DXA scores. According to the T-scores calculated from femur neck (FN) and lumbar spine (LS), subjects divided into 3 groups as following: a) normal: T-score is greater than -1 SD (standard deviation), b) osteopenia: T-score is between -1 and -2.5 SD, c) osteoporosis: T-score is lower than -2.5 SD.
The Rapid Assessment of Physical Activity (RAPA) aerobic assessment
Physical activity levels of patients were evaluated with The Rapid Assessment of Physical Activity (RAPA) aerobic assessment. Patients divided into 5 groups as following: 1 = sedentary, 2 = underactive, 3 = regular underactive (light activities), 4 = regular underactive, and 5 = regular active).

Locations

Country Name City State
Turkey Istanbul Medeniyet University Faculty of Medicine, Physical Therapy and Rehabilitation Department Istanbul

Sponsors (1)

Lead Sponsor Collaborator
Istanbul Medeniyet University

Country where clinical trial is conducted

Turkey, 

Outcome

Type Measure Description Time frame Safety issue
Primary Waist circumference calculated as cm 2 years
Primary Hip circumference calculated as cm 2 years
Primary Fat percentage Fat percentage and skeletal muscle mass (SMM) was calculated by using bioimpedance analysis (BIA) (Tanita TBF 300; Tanita Corp., Tokyo, Japan) 2 years
Primary Skeletal muscle index Fat percentage and skeletal muscle mass (SMM) was calculated by using bioimpedance analysis (BIA) (Tanita TBF 300; Tanita Corp., Tokyo, Japan). Skeletal muscle index (SMI) was calculated from BIA-based skeletal muscle mass with a formula as SMM/height [m2] 2 years
Primary A body shape index (ABSI) ABSI is measured as waist circumference (m) / (BMI(kg)2/3x Height(m)5/6) 2 years
Secondary The Rapid Assessment of Physical Activity (RAPA) aerobic assessment Physical activity levels of patients were evaluated with The Rapid Assessment of Physical Activity (RAPA) aerobic assessment. Patients divided into 5 groups as following: 1 = sedentary, 2 = underactive, 3 = regular underactive (light activities), 4 = regular underactive, and 5 = regular active). 2 years
See also
  Status Clinical Trial Phase
Completed NCT04807959 - Evaluation of the Effectiveness of a Comprehensive Visceral Adiposity-Focused Anti-Obesity Program
Completed NCT06377358 - Study of Lipolysis of Visceral Reserve Fat Using Tecar Therapy. N/A
Completed NCT04754464 - Clinical Study on the Effect of a Synbiotic on Body Fat Mass N/A
Not yet recruiting NCT04942093 - NUTritional Impact of a Hypocaloric Hyperprotein Diet Before Obesity Surgery N/A
Completed NCT03239782 - The "Metabolically-obese Normal-weight" Phenotype and Its Reversal by Calorie Restriction N/A
Completed NCT06158191 - Long-term Benefits of Abdominal Fat Loss in Abdominally Obese Dyslipidemic Patients (SYNERGIE Study) N/A
Completed NCT02833415 - Visceral Adiposity and Diabetes: Translating Form to Function Using Imaging Phase 4
Recruiting NCT04100616 - A Non-Interventional Pilot Study to Explore the Role of Gut Flora in Obesity
Completed NCT04780828 - Investigation of the Effects of Different Levels of Obesity on the Respiratory System
Completed NCT05895916 - Extreme Exercise and Energy Expenditure (4E) Study N/A
Completed NCT04436419 - Immunometabolic Effects of Non-drug Strategies in the Clinical Management of Obesity: Translational Study N/A
Completed NCT03038620 - Impact of Liraglutide 3.0 on Body Fat Distribution Phase 4
Completed NCT04592107 - The Association of Visceral Adiposity Index With Progression of Chronic Kidney Disease
Completed NCT03542864 - Medical Supervised Duodenal-Enteral Feeding Treatment N/A
Completed NCT05789888 - Genes Variability in Obesity and Normal Body Weight Patients.